Biotech Showcase
Join us virtually
January 10–12, 2022 &January 17–19, 2022

Kevin Healy
Senior VP, Regulatory Affairs, Pharmacovigilance, and Quality at Enzyvant

Profile

Kevin Healy is Enzyvant’s Vice President for Regulatory Affairs, Pharmacovigilance, and Quality. In this role, Kevin leads Enzyvant regulatory strategy and execution, including guiding the company’s lead asset, designated as a Regenerative Medicine Advanced Therapy (RMAT), to an FDA approval in 2021. He also is responsible for oversight of pharmacovigilance and quality systems at Enzyvant and partner organizations.

Kevin brings more than a dozen years of biotech and pharmaceutical regulatory affairs experience to his role at Enzyvant. He was the head of Global Regulatory Affairs at Roivant Sciences and led development and successful filings for several therapies in the autoimmune and rare disease portfolio at Mallinckrodt Pharmaceuticals. He also served on global development teams for hepatitis B and C virus treatments at Gilead Sciences.

Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship in the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill.

Agenda Sessions

  • The Road to an RMAT (Regenerative Medicine Advanced Therapy) FDA Approval

    On Demand

Speakers at this event